DeepMed Research

Jiangsu Province Centers for Disease Control and Prevention

People's Republic of China

Country: People's Republic of China

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.jstd.gov.cn/

Clinical Trials

Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71

Phase 4

Completed

Conditions: Hand, Foot and Mouth Disease

Interventions: Biological: EV71 vaccine

First Posted Date: 2018-07-11

Last Posted Date: 2021-05-24

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 40000

Registration Number: NCT03582761

Locations: 🇨🇳
Hubei Provincial Center for Diseases Control and Prevention, Wuhan, Hubei, China
🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China

Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age

Phase 3

Completed

Conditions: Herpes Zoster

Interventions: Biological: One shot of the varicella-zoster virus vaccine
Biological: one shot of placebo

First Posted Date: 2017-10-19

Last Posted Date: 2021-03-30

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 30000

Registration Number: NCT03314103

Locations: 🇨🇳
Hunan Provincial Center for Disease Control and Prevention, Loudi, Hunan, China
🇨🇳
Jiangsu Province Centers for Disease Control and Prevention, Nanjing, Jiangsu, China
🇨🇳
Zhejiang Provincial Center for Disease Control and Prevention, Hanzhou, Zhejiang, China

Safety of An Oral O1 / O139 Cholera Vaccine (Enteric Capsules)

Phase 1

Completed

Conditions: Safety of the Oral O1 / O139 Cholera Vaccine (Enteric Capsules)

Interventions: Biological: The oral O1 / O139 cholera vaccine (enteric capsules)

First Posted Date: 2017-08-02

Last Posted Date: 2017-08-02

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 60

Registration Number: NCT03237663

Observational Study to Assess Protection to Mumps in Children Received One-dose Mumps-containing Vaccine

Completed

Conditions: Parotid Gland Infection
Fever

First Posted Date: 2016-09-15

Last Posted Date: 2017-06-06

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 7901

Registration Number: NCT02901990

Locations: 🇨🇳
lianshui county CDC, Huaian, Jiangsu, China
🇨🇳
ganyu district CDC, Lianyungang, Jiangsu, China
🇨🇳
tongshan district CDC, Xuzhou, Jiangsu, China

and more 3 locations

A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults

Early Phase 1

Completed

Conditions: Staphylococcus Aureus Infection

Interventions: Biological: Staphylococcus aureus vaccine (60µg/per protein)
Biological: Staphylococcus aureus vaccine (30µg/per protein)
Biological: Staphylococcus aureus vaccine (15µg/per protein)

First Posted Date: 2016-07-01

Last Posted Date: 2016-09-12

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 30

Registration Number: NCT02820883

Locations: 🇨🇳
Taixing county disease control and prevention, Taixing, Jiangsu, China

A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults

Phase 1

Completed

Conditions: Staphylococcus Aureus Infection

Interventions: Biological: High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)
Biological: Placebo
Biological: Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)
Biological: Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)

First Posted Date: 2016-06-17

Last Posted Date: 2017-10-17

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 144

Registration Number: NCT02804711

Locations: 🇨🇳
Xiaokui Hu, Taixing, Jiangsu, China

A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Trivalent influenza vaccine A
Biological: Quadrivalent influenza vaccine
Biological: Trivalent influenza vaccine B

First Posted Date: 2016-03-16

Last Posted Date: 2016-09-01

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 3664

Registration Number: NCT02710409

Locations: 🇨🇳
Guanyun County Center for Disease Control and Prevention, Lianyungang, Jiangsu, China

A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine

Phase 3

Completed

Conditions: Haemophilus Influenza

Interventions: Biological: Hib conjugate vaccine

First Posted Date: 2016-02-26

Last Posted Date: 2017-09-20

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 1992

Registration Number: NCT02692859

A Clinical Trial to Evaluate a Recombinant Hepatitis E Vaccine in Healthy Adults

Phase 1

Completed

Conditions: Hepatitis E

Interventions: Biological: 30μg/0.5ml Hepatitis E vaccine
Biological: 30μg/0.5ml Recombinant Hepatitis E vaccine

First Posted Date: 2015-11-11

Last Posted Date: 2016-09-01

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 60

Registration Number: NCT02603055

Locations: 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China

Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines

Phase 4

Completed

Conditions: Hepatitis A

Interventions: Biological: Attenuated Hepatitis A Vaccine, H2 Strain
Biological: Group A Meningococcal Polysaccharide vaccine
Biological: Inactivated Hepatitis A Vaccine, Lu8 Strain

First Posted Date: 2015-11-10

Last Posted Date: 2015-11-10

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 13500

Registration Number: NCT02601040

Locations: 🇨🇳
Institute of Medical Biology -Chinese Academy of Medical Sciences, Kunming, Yunnan, China
🇨🇳
Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy